Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Telix Pharmaceuticals Converts 15,000 Share Rights into Ordinary Shares
Highlights
Telix Pharmaceuticals Reports Share Rights Conversion
Telix Pharmaceuticals Limited (ASX: TLX) announced on 5 October 2026 that 15,000 share rights had been exercised, resulting in the transfer of an equivalent number of fully paid ordinary shares. The disclosure was made through an Appendix 3G notification lodged with the Australian Securities Exchange. Telix shares were quoted at AU$15.935, up AU$0.525 or 3.406% today.
According to the announcement, the conversion involved share rights classified under the company's existing securities code TLXAP. The rights were converted on 24 August 2026, and the resulting ordinary shares were transferred on 27 August 2026. The company confirmed that the conversion was completed without any cash consideration. The rights had been issued under an employee incentive scheme, while the filing stated that none of the securities involved in this conversion were held by key management personnel or their associates.
Ordinary Shares and Equity Securities on Issue
Following the transfer, Telix Pharmaceuticals reported 339,894,019 fully paid ordinary shares quoted on the ASX. The filing also detailed the company's remaining unquoted equity securities, including performance rights, deferred share rights, share appreciation rights and convertible notes.
These instruments form part of the company's broader equity-based remuneration and incentive arrangements. Such schemes can be used to align employee interests with longer-term corporate performance, subject to the relevant vesting and exercise conditions. The company referred investors to its 2024 and 2025 Annual Reports for further information about the remuneration arrangements associated with the share rights.
Telix Reports Lapse of Additional Conditional Rights
In a separate Appendix 3H announcement dated 5 October 2026, Telix disclosed that 580,663 conditional rights had lapsed on 30 September 2026 because the applicable conditions had not been met or could no longer be satisfied. The affected securities comprised 26,000 US share rights, 76,000 share rights, 221,000 share appreciation rights and 257,663 US performance share appreciation rights issued under the 2025 plan. The company confirmed that no consideration was payable in connection with these lapses. Following the changes, the number of securities in the respective unquoted categories was adjusted accordingly.
TLX Share Price Performance and Outlook
The announcements provide an update on the company's equity incentive arrangements and securities on issue. While the conversion increases the number of ordinary shares represented by the exercised rights, the lapse of conditional rights reduces the number of outstanding instruments in the affected categories. Investors may continue to monitor Telix's regulatory filings and operational updates for further developments.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au